List of Dovato drug patents

Dovato is owned by Viiv Hlthcare.

Dovato contains Dolutegravir Sodium; Lamivudine.

Dovato has a total of 3 drug patents out of which 0 drug patents have expired.

Dovato was authorised for market use on 08 April, 2019.

Dovato is available in tablet;oral dosage forms.

Dovato can be used as treatment of hiv infection.

The generics of Dovato are possible to be released after 24 January, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234985 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(7 years from now)

Exclusivity Exclusivity Expiration
New Combination (NC) Apr 8, 2022
New Indication (I) Aug 6, 2023

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: Treatment of hiv infection


How can I launch a generic of DOVATO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic